Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence
- PMID: 22966447
- PMCID: PMC3420601
- DOI: 10.1155/2012/815315
Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence
Abstract
Improving functional outcome, in addition to alleviating psychotic symptoms, is now a major treatment objective in schizophrenia research. Given the large body of evidence suggesting pharmacological treatments generally have minimal effects on indices of functioning, research has turned to psychosocial rehabilitation programs. Among these, neurocognitive and social cognitive interventions are at the forefront of this field and are argued to target core deficits inherent to the schizophrenia illness. However, to date, research trials have primarily focused on chronic schizophrenia populations, neglecting the early psychosis groups who are often as severely impaired in social and occupational functioning. This theoretical paper will outline the rationale for investigating adjunctive cognitive-based interventions in the early phases of psychotic illness, critically examine the current approach strategies used in these interventions, and assess the evidence supporting certain training programs for improving functional outcome in early psychosis. Potential pathways for future research will be discussed.
Similar articles
-
[What support of young presenting a first psychotic episode, when schooling is being challenged?].Encephale. 2017 Dec;43(6):570-576. doi: 10.1016/j.encep.2017.10.001. Epub 2017 Nov 8. Encephale. 2017. PMID: 29128195 Review. French.
-
Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.Med J Aust. 2019 Nov;211 Suppl 9:S3-S46. doi: 10.5694/mja2.50383. Med J Aust. 2019. PMID: 31679171
-
Insight across mental disorders: A multifaceted metacognitive phenomenon.Psychiatriki. 2019 Jan-Mar;30(1):13-16. doi: 10.22365/jpsych.2019.301.13. Psychiatriki. 2019. PMID: 31115349 English, Greek, Modern.
-
Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention.Schizophr Res. 2010 Jun;119(1-3):1-10. doi: 10.1016/j.schres.2010.02.1071. Epub 2010 Mar 26. Schizophr Res. 2010. PMID: 20347270 Review.
-
Efficacy of Integrated Social Cognitive Remediation vs. Neurocognitive Remediation in Improving Functional Outcome in Schizophrenia: Concept and Design of a Multicenter, Single-Blind RCT (The ISST Study).Front Psychiatry. 2022 Jun 21;13:909370. doi: 10.3389/fpsyt.2022.909370. eCollection 2022. Front Psychiatry. 2022. PMID: 35800017 Free PMC article.
Cited by
-
The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial.Trials. 2015 Jan 27;16:25. doi: 10.1186/s13063-014-0542-8. Trials. 2015. PMID: 25623736 Free PMC article. Clinical Trial.
-
Compensatory Interventions for Cognitive Impairments in Psychosis: A Systematic Review and Meta-Analysis.Schizophr Bull. 2020 Jul 8;46(4):869-883. doi: 10.1093/schbul/sbz134. Schizophr Bull. 2020. PMID: 32052837 Free PMC article.
-
A Synthetic Literature Review on the Management of Emerging Treatment Resistance in First Episode Psychosis: Can We Move towards Precision Intervention and Individualised Care?Medicina (Kaunas). 2020 Nov 24;56(12):638. doi: 10.3390/medicina56120638. Medicina (Kaunas). 2020. PMID: 33255489 Free PMC article. Review.
-
European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.Eur Psychiatry. 2022 Sep 5;65(1):e58. doi: 10.1192/j.eurpsy.2022.2316. Eur Psychiatry. 2022. PMID: 36059109 Free PMC article.
-
Heterogeneity in treatment outcomes and incomplete recovery in first episode psychosis: does one size fit all?Transl Psychiatry. 2022 Nov 17;12(1):485. doi: 10.1038/s41398-022-02256-7. Transl Psychiatry. 2022. PMID: 36396628 Free PMC article. Review.
References
-
- Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin. 2005;31(1):5–19. - PubMed
-
- Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. British Journal of Psychiatry. 1998;172(33):53–59. - PubMed
-
- Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience. 2000;250(6):274–285. - PubMed
-
- Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-Month follow up of a high-risk (“prodromal”) group. Schizophrenia Research. 2003;60(1):21–32. - PubMed
LinkOut - more resources
Full Text Sources
Medical